Lenzetto (Estradiol)

Estradiol in Lenzetto penetrates the skin and enters the bloodstream, where it binds to estrogen receptors ERα and ERβ in target cells. This receptor activation modulates gene transcription, producing estrogenic effects that alleviate menopausal symptoms, support bone health, and restore normal hormonal balance.

The specific dose and patch change interval for Lenzetto are determined by the prescribing clinician based on the individual’s age, severity of symptoms, and overall health status. Patients should follow the prescriber’s instructions and not adjust the dosing schedule on their own.

Lenzetto is contraindicated during pregnancy because exogenous estrogen can affect fetal development. It is also generally not recommended while breastfeeding, as estradiol may pass into breast milk and influence infant hormonal balance. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with oral estradiol tablets, the transdermal patch bypasses first‑pass hepatic metabolism, potentially reducing liver‑related side effects and offering more stable plasma concentrations. Unlike injectable estrogens, the patch provides continuous delivery without the need for injections, improving convenience and adherence for many patients.

Lenzetto patches should be stored at room temperature, below 25 °C, in their original sealed packaging. Keep them away from direct sunlight, moisture, and excessive heat. Do not expose the patch to temperatures above the recommended range, as this could affect drug stability and adhesion.

Lenzetto is applied to clean, dry, intact skin on the lower abdomen or buttock. The patch is typically worn for a specified number of days (as directed by the prescriber) and then replaced with a new patch at the same site or a different approved site. Patients should rotate application sites to minimize skin irritation.

Serious risks include venous thromboembolism, stroke, myocardial infarction, gallbladder disease, severe allergic reactions, and endometrial hyperplasia. Patients should seek immediate medical attention if they experience unexplained leg pain, sudden shortness of breath, chest pain, severe abdominal pain, or signs of an allergic reaction such as swelling of the face or throat.

Lenzetto should not be used by women with a known history of estrogen‑dependent cancers (e.g., breast or endometrial cancer), active thromboembolic disease, uncontrolled hypertension, liver disease, or those who are pregnant. Additionally, individuals with known hypersensitivity to estradiol or any component of the patch should avoid its use.